Evidence map›Paper›PMID 42149441›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Genetic Engineering of Human Keratinocytes Using CRISPR/Cas9 Ribonucleoprotein Complexes or Modified Cas9-Encoding mRNAs.

Jaimy A Klijnhout, Eline A W Senders, Ellen H van den Bogaard, Jos P H Smits

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jaimy A KlijnhoutDepartment of Dermatology, Research Institute for Medical Innovation, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands.ORCID https://orcid.org/0009-0003-6470-7822
Eline A W SendersDepartment of Dermatology, Research Institute for Medical Innovation, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands.ORCID https://orcid.org/0009-0005-6034-1071
Ellen H van den BogaardDepartment of Dermatology, Research Institute for Medical Innovation, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0003-4846-0287
Jos P H SmitsDepartment of Dermatology, Research Institute for Medical Innovation, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands. Jos.PH.Smits@Radboudumc.nl.ORCID https://orcid.org/0000-0003-0915-8624

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR/Cas9 is a straightforward genome-editing technique that is implemented across disciplines and research areas. However, in keratinocytes, CRISPR/Cas9 can be particularly difficult due to variable genome-editing efficiency, reduced cell viability, and difficulties during (sub)cloning of gene-edited keratinocyte populations. Here, we provide a step-by-step detailed protocol for the genetic manipulation of human (primary) keratinocytes, including widely accepted procedures for the analysis of CRISPR/Cas9 efficiency, (sub)cloning procedures to select heterozygous or homozygous keratinocytes, and off-target genome-editing analysis.

Indexed as

CRISPR-Cas SystemsGene EditingGenetic EngineeringKeratinocytesRibonucleoproteinsRNA, MessengerElectroporationHumansRibonucleoproteinsRNA, MessengerCationic vectorsCRISPR/Cas9ElectroporationKeratinocyteLaboratory protocolLipofectamineN/TERT-1N/TERT-2GRibonucleoprotein

Identifiers

PMID42149441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.